A FAERS database study on visual impairment adverse events associated with three long-acting insulin analogues. [PDF]
Zhong L, Cao W, Liu X, Wen T, Yan J.
europepmc +1 more source
A paradigm shift in diabetes care: clinical implications of once-weekly insulin icodec. [PDF]
Abid MA, Abid MH, Afzal MD.
europepmc +1 more source
Simple Hydrodynamic Molecular Weight Model for Rapid Assessment of Therapeutic Protein Oligomerization States in Formulation. [PDF]
Lu J, Chen K.
europepmc +1 more source
Effects of exogenous detemir and glargine insulin on the detection of endogenous C-peptide and endogenous insulin. [PDF]
Wang YT, Ma YF, Zheng Y, Ou Y, Zhou YK.
europepmc +1 more source
Case Report: Rapid loss of endogenous insulin secretion and reversible subcutaneous insulin resistance following exogenous insulin exposure in a patient initially diagnosed with type 2 diabetes. [PDF]
Wen S +6 more
europepmc +1 more source
Is There a Better Day of the Week to Administer Semaglutide or Tirzepatide? A Systematic Literature Review. [PDF]
La Vignera S, Condorelli RA.
europepmc +1 more source
Syndromic diabetes and hypergonadotropic hypogonadism in a boy with a 12q24.31-32 chromosomal deletion involving <i>HNF1A</i>, <i>DHX37</i>, and <i>SETD1B</i>. [PDF]
Nakagawa T +7 more
europepmc +1 more source
Impact of Time of Injection on the Efficacy and Safety of iGlarLixi Versus IDegAsp in Chinese People With Type 2 Diabetes: Exploratory Analysis of the Soli-D Study. [PDF]
Li X +8 more
europepmc +1 more source
Beyond Glycemic Control: Real-World 12-Month Effects of Insulin Glargine/Lixisenatide on Weight, Endogenous Insulin Secretion, and Albuminuria. [PDF]
Ozturk S, Akyol EMB.
europepmc +1 more source
iGlarlixi for the simplification of more complex insulin regimens in type 2 diabetes patients with good glycaemic control. [PDF]
Taybani ZJ +10 more
europepmc +1 more source

